Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary
Recommended Citation
Leary EB, Van Dongen HPA, Drake C, Bogan R, Jaeger J, Streicher C, and Tabuteau H. Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary. Postgrad Med 2025; 137(3-4):209-219.
Document Type
Article
Publication Date
5-5-2025
Publication Title
Postgraduate medicine
Abstract
What is this summary about? The SHARP study looked at the effects of a medication called solriamfetol in people with obstructive sleep apnea (sleep apnea for short) who were very sleepy during the day (called excessive daytime sleepiness) and had trouble with things like thinking, concentrating, and remembering (called cognitive impairment). In people with sleep apnea, breathing is regularly interrupted during sleep. This can lead to many problems, including excessive daytime sleepiness and cognitive impairment.In previous studies, people with sleep apnea and excessive daytime sleepiness who took solriamfetol felt more awake during the day compared with people who took an identical tablet with no medication (called a placebo). The SHARP study looked at the effects of solriamfetol on symptoms related to cognitive impairment. To avoid bias from people’s personal feelings about their cognition, the cognitive function of people who participated in the study was measured by a cognitive performance test (called objective cognitive function). Subjective ratings were also used; these measured people’s personal feelings about their cognitive function (called subjective cognitive function), the severity of their cognitive impairment, and their sleepiness during the day.
What are the key takeaways? In the SHARP study, people had more improvement in their objective cognitive function when taking solriamfetol than when they took placebo, and this benefit lasted for 8 hours. People also reported that their subjective cognitive function had improved, their cognitive impairment was less severe, and their daytime sleepiness was better with solriamfetol. The most common side effects were nausea and anxiety.
What were the main conclusions reported by the researchers? These findings show that solriamfetol can improve cognitive function in people with cognitive impairment related to sleep apnea and excessive daytime sleepiness.
PubMed ID
40325548
Volume
137
Issue
3-4
First Page
209
Last Page
219
